ArticleEClinicalMedicine2026

Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study.

Wynne Wijaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.